How to solve the big challenges of cell and gene therapy manufacturing
There has never been more investment and excitement around the cutting-edge medicine being developed under the umbrella of cell and…
There has never been more investment and excitement around the cutting-edge medicine being developed under the umbrella of cell and…
With GlobalData currently forecasting that the data and analytics market in pharma will reach $2.1bn by 2028, real-world data is…
The cell and gene therapy (CGT) market is forecast to be worth almost $80bn by 2030, but issues must be…
Only 9% of life sciences professionals understand U.S. and EU artificial intelligence (AI) regulations well.[1] Let that sink in. While your…
Pharmaceutical supply chains continue to be disrupted by a range of geopolitical factors, including global conflict, economic uncertainty, and especially…
The global cell and gene therapy (CGT) market is expanding at a rapid rate, and will be worth $76bn by…
With the MS Trust estimating that more than 2.9 million people worldwide have multiple sclerosis (MS), new therapies are urgently…
Every stage of the pharmaceutical supply chain is critical if life-saving drugs are to make it to market – and…
We’ve all seen the statistics – over 7,000 rare diseases, and only 5% have any approved treatments. It’s a situation…
A new report from leading global contract research organization Novotech examines the triple-negative breast cancer global clinical trial landscape in…